Scanlan Sean F. 4

What Happened

• Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, exercised 53,500 stock options on Jan 21, 2026 at $0.72 per share, paying $38,520. The filing also shows a related derivative entry for 53,500 shares on Jan 21 (reported at $0). On Jan 22, 2026 he received a grant of 262,500 restricted stock units (RSUs) with no cash price.

Key Details

• Transactions and prices:
  • 2026-01-21: Exercise/conversion (code M) — 53,500 shares @ $0.72; total cash paid $38,520.
  • 2026-01-21: Related derivative entry (code M) — 53,500 shares @ $0.00 (reported as derivative).
  • 2026-01-22: Grant/award (code A) — 262,500 RSUs @ $0.00.
• Shares owned after the transactions: filing does not provide a single consolidated post-transaction total. Footnotes note sizeable RSU holdings (see next point).
• Notable footnotes:
  • F2: The 262,500 RSUs vest in equal annual installments over 4 years, with the first installment vesting Jan 22, 2027 and the last on Jan 22, 2030, subject to continued service.
  • F1 and F3: the filing also references existing RSU balances (e.g., includes 283,948 RSUs and includes 511,291 RSUs), indicating material unvested RSU holdings; F4 notes the exercised option originally vested over 2016–2020.
• Timeliness: Transaction dates are Jan 21–22, 2026; the Form 4 was filed Jan 23, 2026 — generally within the typical 2-business-day reporting window.

Context

• The Jan 21 activity appears to be a cash exercise of options (insider paid $0.72/share) rather than an immediate sale — the filing does not show any shares sold. The Jan 22 entry is a standard RSU grant that vests over four years, so those shares are subject to future vesting and continued employment and are not immediately tradable. The separate $0 derivative line likely reflects internal conversion/recording mechanics tied to the option exercise rather than a new cashless sale.